Skild AI Expands Generalized Robot Intelligence Across Industries With ABB Robotics, Universal Robots, and NVIDIA

 

Skild AI is partnering with ABB Robotics and Universal Robots to deploy its omni-bodied robot brain across industries and applications, from factory floors to collaborative systems, without task-by-task reprogramming


PITTSBURGH, March 17 (Bernama-GLOBE NEWSWIRE) -- Skild AI, a pioneer in building generalized robot intelligence for any embodiment, today announced expanded collaborations with NVIDIA, ABB Robotics, and Teradyne Robotics’ Universal Robots (UR) and Mobile Industrial Robots (MiR) to deploy its AI-powered robot brain across multiple industries and applications. The company’s technology is to be shipped to production environments, including high-precision assembly for NVIDIA Blackwell systems with Foxconn.

Skild AI’s mission is to bring AI into the physical world through its general-purpose robotics foundation model, Skild Brain. It is an omni-bodied brain designed to control any kind of robotic hardware – any robot, any task, one brain. This enables a powerful data flywheel: the brain can combine data from different robot deployments and use it to improve itself, which in turn helps scale additional deployments that generate even more data.

Skild AI’s partnership with these robotics OEMs will accelerate this data flywheel through the large-scale deployment of Skild Brain. Conventionally, industrial robots must be carefully programmed by human experts, task by task, which is difficult to scale and often impossible to automate. Skild’s omni-bodied AI brain offers a fundamentally different approach: learning directly from data.

“Robotics is at an inflection point similar to where LLMs were a few years ago,” said Deepak Pathak, CEO of Skild AI. “Advances in hardware, simulation, and large-scale AI training are making general-purpose robot intelligence possible. By training an omni-bodied intelligence that transfers skills across embodiments and environments, we’re shifting from programming tasks to building systems that continuously learn and improve, even during deployment.”

“This partnership helps us to bring automation and robotics for SMBs and non-traditional manufacturing and unlocks large-scale deployment of Skild Brain,” said Abhinav Gupta, President at Skild AI.

Building Omni-Bodied Intelligence With NVIDIA’s Open Robotics Platform

Training a robotic foundation model requires a large diversity of data, a process known as pretraining. For large language models such as ChatGPT, this data can be gathered from the Internet, but in robotics, there is no equivalent “Internet of robot data.” Skild AI’s approach is to leverage (a) internet scale human videos and (b) large-scale robot simulations.

To realize this, Skild AI leverages NVIDIA’s open robotics platform, using the open NVIDIA Isaac Lab and NVIDIA Isaac Sim robot learning and simulation frameworks and the Newton physics engine to create physically accurate simulations. These tools allow the Skild Brain to simulate millennia of experience in realistic digital environments, across tasks and settings, before deploying in the real world. Once the Skild Brain is pretrained, it is then finetuned using small amounts of real robot data.

To extend learning beyond the limits of collected real-world data, Skild AI incorporates NVIDIA Cosmos world foundation models to generate and augment synthetic data, improving robustness and sim-to-real transfer. Once trained, the generalized robot brain runs on systems powered by NVIDIA Jetson, enabling real-time, low-latency AI inference on deployed robots.

“Physical AI is transforming the world’s largest industries,” said Deepu Talla, Vice President of Robotics and Edge AI at NVIDIA. “Built on NVIDIA’s open robotics platform and accelerated computing, Skild AI’s generalized robot brain demonstrates how foundation models trained in simulation can be deployed on real robots at scale.”

Deploying Generalized Robot Intelligence With ABB Robotics and Universal Robots

Through its collaboration with NVIDIA, Skild AI is working closely with ABB Robotics and Universal Robots to integrate its omni-bodied brain into their robot portfolios. By embedding Skild Brain’s shared intelligence layer into widely deployed industrial robots, manufacturers can extend automation into more dynamic, highly variable, and complex applications without needing to build task-specific code for every workflow.

“At ABB Robotics, we see more autonomous and versatile robotics (AVR™) as the enabler for the next era of flexible and efficient manufacturing,” said Marc Segura, President, ABB Robotics. “Integrating Skild AI’s generalized robot intelligence into our portfolio will help customers scale industrial-grade automation more quickly and address increasingly complex applications scenarios across a broad range of industries.”

“Universal Robots was founded to make automation simple and accessible,” said Jean-Pierre Hathout, CEO, Universal Robots. “Working with Skild AI and NVIDIA allows us to bring advanced AI capabilities to our cobots — enabling them to handle more dynamic, variable tasks across industries.”

“This partnership helps us to bring automation and robotics for SMBs and non-traditional manufacturing and unlocks large-scale deployment of Skild Brain,” said Abhinav Gupta, President, Skild AI.

Early Success in Advanced Manufacturing

Skild AI is working with partners to deploy its solution in enterprise applications for advanced manufacturing. In partnership with Foxconn, Skild AI is planning to ship its omni-bodied brain to control dual-arms on NVIDIA’s Blackwell GPU production lines, performing complex assembly operations requiring precise manipulation and adaptability.

About Skild AI

Skild AI builds omni-bodied robot intelligence: AI-powered robot brains designed to operate any kind of robot for any application. By training foundation models and deploying them in real-world environments, Skild AI is advancing adaptable, intelligent robotics across industries. Today’s announcement with robot OEMs marks a key milestone in moving this technology towards generating real-world economic value.

A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e616c088-edb9-4604-ba40-89b88498bc7b

Contacts:

Aditya Raghunathan
aditya@skild.ai

Skild
press@skild.ai 

SOURCE: Skild AI

AM BEST: AUSTRALIA’S GUILD INSURANCE CREDIT RATINGS UNCHANGED AFTER PARTNERSHIP

KUALA LUMPUR, March 11 (Bernama) -- AM Best has commented that the financial strength rating of A- (Excellent) and the long-term issuer credit rating of “a-” (Excellent) of Australia’s Guild Insurance Limited (GIL) remain unchanged following the announcement of its new strategic partnership with EML Group.

EML Group comprises Employers Mutual Limited and ASWIG Management Pty Ltd as trustee for the ASWIG Management Trust on behalf of its underlying investor shareholders.

Under the terms of the transaction announced on Feb 25, GIL’s ultimate owner, The Pharmacy Guild of Australia (PGOA), has agreed to sell a majority stake in GIL to Employers Mutual Limited and the shareholders of ASWIG Management Pty Ltd.

Meanwhile, a minority stake will be retained by Guild Group Holdings Limited, the commercial arm of the PGOA. The transaction is expected to close on or around July 1 and remains subject to regulatory approval, according to AM Best in a statement.

A global credit rating agency, news publisher and data analytics provider specialising in the insurance industry, AM Best expects the prospective change to the shareholding structure to have a neutral impact on GIL’s credit rating fundamentals.

-- BERNAMA

Living Better with Cancer: How Personalised Treatment is Redefining Cancer Care

^{Consultant Clinical Oncologist, Dr Marfu’ah Nik Eezamuddeen (left) and Registered Counsellor, Ms Kuah Rui Ning (right)}


KUALA LUMPUR, March 10 (Bernama) -- For many, a cancer diagnosis still feels like an immediate loss of control - a future defined by hospital corridors, aggressive treatments and lives put on hold. But cancer care today is undergoing a profound transformation. As science deepens its understanding of the disease, treatment is no longer driven by a one-size-fits-all approach. Instead, it is becoming more precise, more personal and increasingly focused on helping patients live well, not just survive.
 
In conjunction with World Cancer Day, themed “United by Unique”, this evolution reflects a fundamental truth: while cancer may share the same name, no two patients experience it in the same way. Each person’s biology is different, as are their lives, circumstances, and the hopes, fears and priorities that shape their journey.
 
At Subang Jaya Medical Centre (SJMC), this philosophy of personalised and people-centred care is shaping how patients experience cancer treatment today. Drawing insights from Consultant Clinical Oncologist Dr Marfu’ah Nik Eezamuddeen and Registered Counsellor Ms Kuah Rui Ning, it highlights how combining medical innovation with emotional and psychological support is helping many patients live longer and better with cancer.
 
Seeing the Person Beyond the Diagnosis
“When I sit across a patient, I am not just seeing a diagnosis. I am seeing a life, a family and a future they are afraid of losing,” says Dr Marfu’ah.
 
Over the past decade, cancer treatment has undergone a major transformation. Previously, treatment decisions were largely based on where the cancer started, such as the breast or lung, and followed standard protocols.
 
Today, doctors look much deeper. Through molecular pathology testing, specialists can study the unique biology and behaviour of each cancer. This allows treatment to be tailored according to the individual cancer profile rather than relying solely on conventional approaches.
 
“Two patients may both have breast or lung cancer, yet their cancers and their lives can be very different,” she explains. “Personalised care recognises that difference.”
 
In Malaysia, increased access to molecular testing has significantly changed how cancer care is delivered. These tests help oncologists make earlier and more precise treatment decisions, often identifying therapies that are more effective and better tolerated.
 
For patients, this brings clarity at a time that can feel overwhelming.
 
“Instead of uncertainty, patients are able to understand why a certain treatment is recommended for them,” Dr Marfu’ah says. “That understanding gives them confidence and a greater sense of control.”
 
Moving Beyond Traditional Treatment Fears
Many Malaysians still associate cancer treatment with harsh chemotherapy and severe side effects. While chemotherapy and radiotherapy remain essential tools, newer options have changed how patients experience treatment.
 
Advances such as immunotherapy and oral targeted therapy allow treatment to target cancer cells more precisely. In some cases, these therapies are better tolerated and allow patients to continue with daily routines.
 
“Cancer treatment today is often far more manageable than people expect,” says Dr Marfu’ah. “Many patients are still able to work, care for their families and maintain their independence during treatment.”
 
These developments have been particularly meaningful in cancers such as lung and breast cancer, where survival outcomes have improved significantly. “I have seen patients live years longer than what was previously expected,” she shares. “But what matters most is not just how long they live, but how they live.”
 
She recalls young mothers watching their children grow up and individuals continuing their careers while undergoing treatment. “This shift reminds us that cancer care is no longer only about extending life. It is also about preserving purpose, identity and meaning.”
 
Treatment Shaped by Real Lives
While medical tests guide clinical decisions, personalised care goes far beyond laboratory results.
 
“A patient’s background, lifestyle, beliefs and family responsibilities matter deeply,” Dr Marfu’ah explains. “Some prioritise longevity, while others prioritise independence or being present for their children.”
 
Listening to these priorities allows treatment plans to reflect what matters most to each patient. “My role is not just to treat cancer,” she says. “It is to help patients walk through treatment with clarity, dignity and as little fear as possible.”

This approach becomes especially important when patients are coping with fear after diagnosis.
 
“Fear is a natural response,” she adds. “I often tell patients that it is normal to feel afraid. We will take this one step at a time, together.”
 
By explaining treatment plans clearly and outlining available support, many patients begin to realise that a cancer diagnosis does not automatically mean the end of their life or identity.
 
“Modern cancer care is a partnership between the medical team, the patient and their loved ones,” she says.
 
The Emotional Journey Behind the Illness
While medical advances play a vital role, cancer affects far more than the body alone. The emotional journey can be just as complex and challenging.
 
From the counselling perspective, Ms Kuah Rui Ning sees cancer as a deeply personal experience that unfolds in stages. “At diagnosis, it often feels like a sudden storm,” she says. “There is shock, disbelief, fear and vulnerability. Many patients feel their world has paused.”
 
As treatment begins, the emotional landscape shifts. “I often describe it as a marathon,” she explains. “There is anxiety and determination at the start, but as side effects build, patients reach what I call the long middle.”
 
Fatigue, emotional exhaustion and loss of motivation are common during this phase. Yet she also witnesses moments of unexpected strength. “Many patients realise they are stronger than they believed. They discover strength they never knew they had.”
 
Survivorship, she adds, can be equally complex. “While there is relief and hope, there can also be fear of recurrence and anxiety about trusting the body again. Learning to rebuild a sense of normal takes courage.”
 
Across every stage, one need remains constant. “Patients want to be heard,” she says. “They want to know their feelings are valid.”
 
Helping Patients Express What is Hard to Put into Words
From a counselling perspective, understanding how a patient is coping emotionally is an important part of care. Ms Kuah explains that she often uses simple assessment tools such as a distress thermometer, which allows patients to rate their emotional or physical distress on a scale.
 
“For many patients, feelings like fear or anxiety can be difficult to describe,” she says. “This tool helps make those emotions more concrete and opens a conversation about what is truly weighing on them.”
 
Beyond verbal conversations, she also incorporates expressive arts therapy for selected patients. Through drawing, colours or creative expression, patients are able to communicate emotions that may feel overwhelming or difficult to articulate.
 
“The process creates a safe and supportive space for reflection,” she explains. “It allows patients to express their experiences in a gentler way and often helps them reconnect with themselves during a very uncertain time.”
 
Caring for the Whole Person
People centred cancer care extends far beyond medical treatment. It is about supporting emotional, mental and social wellbeing alongside physical health.
 
“To me, it is not just treating a disease,” Ms Kuah explains. “It is caring for the whole person.”  Families and caregivers play an equally important role. Counselling helps strengthen these support systems by offering education, emotional support and guidance in communication.
 
Research indicates that emotionally supported caregivers demonstrate improved coping abilities, greater confidence in their caregiving role, reduced anxiety, and enhanced marital and family relationships. Such interventions help caregivers feel more prepared and less distressed, which in turn is likely to lead to more positive outcomes for patients.
 
Living Better with Cancer
Medical and psychological care are deeply connected. Emotional support has been shown to influence treatment tolerance, motivation and overall wellbeing.
 
“When patients feel supported, we often see improvements in rest, appetite and confidence,” Ms Kuah shares. “These factors affect how the body copes with treatment.”
 
In challenging cases, such as patients undergoing intensive therapy for nasopharyngeal cancer, psychological care can help individuals persevere through difficult side effects. “When patients understand their emotions and learn coping strategies, they move through treatment not as passive recipients, but as resilient individuals.”
  
United by Unique Journeys
World Cancer Day reminds us that while cancer may look similar on scans or reports, no two journeys are ever the same. Being “United by Unique” means recognising that science and compassion must walk hand in hand. It means treating the disease while never losing sight of the person behind it.
 
Today, with advances in personalised medicine and a growing emphasis on emotional support, cancer care is no longer solely about survival. It is about helping patients live with meaning, dignity and hope.
 
For more information on SJMC and its services, visit https://subangjayamedicalcentre.com/.
 
 
ABOUT SUBANG JAYA MEDICAL CENTRE (SJMC)
SJMC is part of Asia OneHealthcare (A1Health), a leading healthcare provider in the region. With an impeccable reputation as one of Malaysia's most trusted private medical centres, SJMC is best known for its clinical outcomes. The hospital is an award-winning 442-bed multi-disciplinary tertiary hospital providing comprehensive and complex care in all specialities.
 
It is one of the few internationally accredited Joint Commission International (JCI) hospitals in Malaysia and Malaysian Society for Quality in Health (MSQH) accredited. SJMC’s laboratory is also an internationally recognised MS ISO 15189 accredited since 2009. In 2024, SJMC Oncology (Cancer), Cardiology, Gastroenterology and Paediatric Services are certified by Australian Council of Healthcare Standards (ACHS) International as a Centre of Excellence, making it the first in Asia-Pacific.
 
SJMC is recognised as a finalist for the Flagship Medical Tourism Hospital Programme 2023 – 2025 by Malaysia Healthcare Travel Council (MHTC) to establish Malaysia as a globally renowned icon for healthcare travel, delivering exceptional end-to-end patient experiences anchored on medical excellence, service excellence, and international branding. It receives both local patients across Malaysia and international patients across the Asia Pacific with over 47,000 admissions and almost half a million outpatient visits annually.
 

SOURCE: Subang Jaya Medical Centre (SJMC)

Xsolla Expands Global Payments Portfolio Across 18 Markets

KUALA LUMPUR, March 4 (Bernama) -- Xsolla, a global video game commerce company, has announced a major expansion of its global payments portfolio across 18 markets in Europe, the Middle East, Africa, and Asia. 

According to Xsolla in a statement, this expansion enables developers to reach new paying users, improve conversion rates, and deliver payment experiences tailored to local player preferences.

Xsolla President, Chris Hewish said localised payments are among the most powerful drivers of conversion and growth for video game developers.

“By expanding our payment coverage across 18 markets, we are giving developers all the things they need to reach players with the payment methods they already trust without adding complexity to their operations,” added Hewish.

The newly supported payment methods include Local Amazon Pay in Japan, which provides fully localised checkout experiences in Japanese yen for over 100 million registered Amazon Japan accounts.

In Iraq, Zain Cash is expanding access to mobile-first payment options, where mobile numbers serve as primary digital identities for more than 40 million people, while Tamara, which operates in Saudi Arabia and the United Arab Emirates, offers flexible Buy Now, Pay Later options to more than 15 million users.

M-Pesa in Tanzania unlocks access to the country’s leading mobile money ecosystem with over 26 million accounts, whereas Zamtel in Zambia supports mobile money transactions for more than 4.3 million subscribers, covering over 20 per cent of the market.

Across Europe, the Aircash app and vouchers are now available in 12 countries, including Germany, Italy, Spain, Poland, and Austria, offering localised digital wallet and voucher options through a network of over 200,000 cash-loading points.

These integrations provide a seamless, localised checkout experience, allowing players to pay in familiar currencies using trusted local methods. For developers, this translates to broader global reach, improved conversion rates, and simplified operations without requiring custom payment integrations or local infrastructure.

-- BERNAMA

IMMUNOSCAPE INKS MOU WITH US CANCER CENTRE, SECURES INVESTMENT

KUALA LUMPUR, March 5 (Bernama) -- ImmunoScape Pte Ltd, a clinical-stage biotechnology company, has announced the execution of a memorandum of understanding (MoU) with a premier National Cancer Institute (NCI)-designated Comprehensive Cancer Center in the United States (US).

The partnership will fast-track ImmunoScape’s "Seed and Boost" platform into the clinic, with the company collaborating with the cancer centre to launch an investigator-initiated clinical trial targeting Wilms Tumor 1 (WT1)-positive solid tumours.

The trial will focus on four difficult-to-treat indications, namely ovarian, mesothelioma and other high-unmet-need solid tumours such as pancreatic and colorectal cancers. The study is scheduled to dose its first patients by September 2026.

According to a statement, the programme leverages ImmunoScape’s differentiated "Seed and Boost" strategy to address persistence and exhaustion challenges commonly seen in traditional cell therapies.

The "Seed" consists of autologous T-cells engineered with a high-affinity T-cell receptor (TCR) targeting the intracellular antigen WT1, while the "Boost" is a clinical-stage fusion protein that selectively expands and activates WT1-targeting T-cells in patients, mimicking the natural immune synapse while leaving other T-cells unaffected.

Concurrently, the company also announced a strategic investment from Leonardo DiCaprio, who said he hopes to play a small role in helping accelerate ImmunoScape’s development.

In addition, ImmunoScape scientists have been selected to present their research at the American Association for Cancer Research Annual Meeting in April 2026, highlighting growing scientific interest in the "Seed and Boost" mechanism.

-- BERNAMA

Bitget Publishes February 2026 Proof of Reserves, Maintaining 169% Total Reserve Ratio

VICTORIA, Seychelles, March 2 (Bernama-GLOBE NEWSWIRE) -- Bitget, the world’s largest Universal Exchange (UEX), has released its February 2026 Proof of Reserves (PoR), reaffirming full backing of user assets amid continued market volatility and cautious investor sentiment across digital asset markets.

The February snapshot covers BTC, ETH, USDT, and USDC, with corresponding reserve data published on Bitget's Proof of Reserves transparency page. As with previous disclosures, the update includes on-chain wallet attestations and a self-verification tool that allows users to confirm their inclusion in the Merkle tree using anonymized identifiers, preserving both transparency and privacy.

As of the February reporting period, Bitget maintains a total reserve ratio of 169%, remaining well above the industry standard 1:1 benchmark. Asset-specific reserve ratios stand at 352% for BTC, 147% for ETH, 100% for USDT, and 104% for USDC, confirming that all user balances across core assets are fully covered by on-chain reserves.

"Periods of uncertainty are when transparency carries the most weight," said Gracy Chen, CEO of Bitget. "February continued to test market confidence, but our reserves remained consistently over-collateralized. Proof of Reserves is not a reactive disclosure, it's our internal commitment to reflect how Bitget operates through every market cycle."

Despite persistent macro pressure and heightened volatility, Bitget's reserve structure remained stable, ensuring uninterrupted access to user funds and platform operations. Proof of Reserves functions as a core component of Bitget's broader security framework, operating alongside its Protection Fund and continuous risk monitoring systems. Merkle root verification allows users to independently validate balances without exposing personal or account-level data.

As Bitget continues to expand its Universal Exchange model, bringing crypto, tokenized assets, and onchain markets into a unified trading environment, regular Proof of Reserves reporting remains foundational. Ongoing disclosures provide users with a clear, verifiable view into platform solvency, reinforcing trust as market conditions evolve.

To view Bitget’s latest Proof of Reserves, please visit here.

About Bitget

Bitget is the world's largest Universal Exchange (UEX), serving over 125 million users and offering access to over 2M crypto tokens, 100+ tokenized stocks, ETFs, commodities, FX, and precious metals such as gold. The ecosystem is committed to helping users trade smarter with its AI agent, which co-pilots trade execution. Bitget is driving crypto adoption through strategic partnerships with LALIGA and MotoGP™. Aligned with its global impact strategy, Bitget has joined hands with UNICEF to support blockchain education for 1.1 million people by 2027. Bitget currently leads in the tokenized TradFi market, providing the industry's lowest fees and highest liquidity across 150 regions worldwide.

For more information, visit: Website | Twitter | Telegram | LinkedIn | Discord

For media inquiries, please contact: media@bitget.com

Risk Warning: Digital asset prices are subject to fluctuation and may experience significant volatility. Investors are advised to only allocate funds they can afford to lose. The value of any investment may be impacted, and there is a possibility that financial objectives may not be met, nor the principal investment recovered. Independent financial advice should always be sought, and personal financial experience and standing carefully considered. Past performance is not a reliable indicator of future results. Bitget accepts no liability for any potential losses incurred. Nothing contained herein should be construed as financial advice. For further information, please refer to our Terms of Use.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/aad8d6fd-5e38-4ccf-b6d5-8c7dde36c2c9 


SOURCE: Bitget Limited

DISCLAIMER: BERNAMA MREM are not accountable for any causes of website defacement, misuse, or illegal activities connected to cryptocurrency, blockchain, tokenisation, or bitcoin. This material should not be considered as guidance or an opinion, as it does not constitute financial or investment advice. Use this information at your own risk; we are not liable for any losses or damages caused by the republication of this article.

APPLICATIONS OPEN FOR TERA-AWARD 2026 WITH US$1.15 MLN PRIZE POOL

KUALA LUMPUR, Feb 23 (Bernama) -- The TERA‑Award 2026 has been launched with a total prize pool of US$1.15 million to accelerate breakthrough energy technologies for climate solutions, with applications open until late April. (US$1=RM3.88)

The award has expanded its global reach through strategic collaborations with the United Nations Trade and Development (UNCTAD) and the University of Cambridge Institute for Sustainability Leadership (CISL).

UNCTAD provides UN policy expertise and global networks to connect TERA-Award innovations with international markets for rapid deployment, while CISL strengthens evaluation through world-leading climate/energy research to identify commercially viable projects.

“By collaborating with international organisations and governments worldwide, we aim to accelerate the real-world deployment of TERA‑Award projects and deliver practical technology pathways for the global energy transition,” said TERA‑Award Organising Committee Executive Chairman, Alan Chan Ying-lung.

Founded in 2021 by Dr Peter Lee Ka‑kit, the TERA-Award has attracted nearly 2,000 projects from 76 countries and has awarded a total of US$4.65 million, positioning itself as an international platform combining prize funding, real-world applications, industry collaboration and capital support for frontier climate innovations.

In response to emerging technological challenges, TERA-Award 2026 will introduce two new categories alongside its four established tracks, namely AI × Energy and Next-Generation Energy, according to a statement.

The AI × Energy category promotes the integration of artificial intelligence into energy systems to enhance efficiency and resilience, while the Next-Generation Energy category expands beyond renewables to include advanced nuclear technologies.

Last year’s edition attracted 785 projects and concluded with an award ceremony at the University of Cambridge.

-- BERNAMA